Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.72 |
| ▸ | CLK2 | P49760 | 6/20 | 0.72 |
| ▸ | CLK3 | P49761 | 6/20 | 0.72 |
| ▸ | WNT1 | P04628 | 15/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17095932 | 0.91 | DYRK1A (0.72) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17095617 | 0.90 | DYRK1A (0.73) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17096497 | 0.89 | DYRK1A (0.76) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17095606 | 0.88 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17096113 | 0.88 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17096650 | 0.88 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17096787 | 0.88 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17095689 | 0.88 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17096067 | 0.88 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL17095860 | 0.88 | DYRK1A (0.68) | DYRK1ACLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | claimed |
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-05-10 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | DYRK1A 1/4885CLK2 86/4885CLK3 48/4885 |
| US-20180127377-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | DYRK1A 1/4885CLK2 86/4885CLK3 48/4885 |
| US-10669240-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, WNT1 | DYRK1A 1/4885CLK2 86/4885CLK3 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.